drugset / Trial / NCT05940571
First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is an open, single center Phase Iclinical trial to evaluate the safety, tolerability, and preliminary efficacy of MBF-362 in patients with solid tumors.
Timeline
- Start
- 2022-11-24
- Primary completion
- 2024-11-26
- Completion
- 2025-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBF-362 | Unknown | 128.7 mg | Oral |
| Subject | MBF-362 | Unknown | 257.4 mg | Oral |
| Subject | MBF-362 | Unknown | 514.8 mg | Oral |
| Subject | MBF-362 | Unknown | 772.2 mg | Oral |